Sensus Healthcare Opens Tel Aviv Office to Expand Footprint in Israel, the Middle East & Europe

BOCA RATON, Fla., Feb. 7, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announced today that the Company is opening a new office in Tel Aviv to deepen its presence in Israel, the Middle East and Europe—while continuing to bring Sensus' innovative SRT treatment to patients all over the world who are afflicted with both non-melanoma skin cancers and keloids.

"Given that Sensus already has SRT-100 Vision™ systems in Israel—the epicenter of cutting-edge aesthetic dermatology—opening an office in Tel Aviv is an obvious and natural next step for our Company as we continue to bring our highly effective SRT treatment to patients in need all over the world," said Joe Sardano, Sensus Healthcare's CEO.

"Sensus' commitment to non-invasive dermatological technology makes entering this progressive market a very logical choice," added Kal Fishman, Sensus Healthcare's CTO. "A deeper foothold in Israel gives us access to collaborate with some of the most creative minds in the industry, which will ultimately help us to improve our technologies and expand our footprint across the globe."

Sensus' current SRT-100 Vision systems are installed at the Beilinson Hospital / Rabin Medical Center in Petah Tikva and Ichilov Hospital in Tel Aviv. The SRT-100 Vision features a unique integration of multimodality therapy and image-guidance technologies with software integration to provide enhanced precision, safety and quality in delivering SRT, electronic brachytherapy (eBx) and Grenz Ray therapy (GRT) in a seamlessly integrated and scalable platform.

The device allows for basal and squamous cell carcinomas, as well as keloid tissue, to be assessed with thorough and precisely targeted treatment. The SRT-100 Vision also allows physicians to better examine how the lesion is progressing with each treatment session and records each session for the patient's records via the LesionCam™. The SRT-100 Vision received FDA clearance for the treatment of non-melanoma skin cancers and keloids in 2015.

About Sensus Healthcare 
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiotherapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.

Media Contacts:
Caitlin Kasunich / Kathryne Hunter
KCSA Strategic Communications
212-896-1241 / 212-896-1204
[email protected] / [email protected] 

SOURCE Sensus Healthcare

Related Links

http://www.sensushealthcare.com